Cargando…

The advantage of chimeric antigen receptor T cell therapy in pediatric acute lymphoblastic leukemia with E2A-HLF fusion gene positivity: a case series

The E2A-HLF fusion gene is a very poor biomarker in acute lymphoblastic leukemia (ALL) because of its high relapse risk, even with the most intensive chemotherapy and hematopoietic stem cell transplantation (HSCT). Here, we analyzed four cases diagnosed with E2A-HLF fusion gene-positive B-ALL and tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Shuiyan, Lu, Jun, Su, Dongni, Yang, Fan, Zhang, Yongping, Hu, Shaoyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041607/ https://www.ncbi.nlm.nih.gov/pubmed/33880339 http://dx.doi.org/10.21037/tp-20-323

Ejemplares similares

Improved outcomes in E2A::HLF positive B-cell acute lymphoblastic leukemia by chimeric antigen receptor T cell therapy and BCL-2 inhibitor
por: Chen, Shumin, et al.
Publicado: (2023)

TCF3-HLF-Positive Acute Lymphoblastic Leukemia Resembling Burkitt Leukemia: Cell Morphologic and Immunophenotypic Findings
por: Li, Meng-Ju, et al.
Publicado: (2022)

TCF3::HLF acute lymphoblastic leukemia: still challenging to cure thirty years later
por: Tasian, Sarah K.
Publicado: (2023)

Aurora A kinase as a target for therapy in TCF3-HLF rearranged acute lymphoblastic leukemia
por: Leonard, Jessica, et al.
Publicado: (2021)

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options
por: Fischer, Ute, et al.
Publicado: (2015)

Cluster of differentiation 19 chimeric antigen receptor T-cell therapy in pediatric acute lymphoblastic leukemia
por: Fu, Zexin, et al.
Publicado: (2020)

The hirudin-like factors HLF3 and HLF4—hidden hirudins of European medicinal leeches
por: Müller, Christian, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Tomuleasa, Ciprian, et al.
Publicado: (2018)

P331: THE ONCOGENIC TRANSCRIPTION FACTOR TCF3::HLF MARKS A DISTINCT ENHANCER-PROMOTER INTERACTION NETWORK IN T(17;19) POSITIVE CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
por: Priebe, Valdemar, et al.
Publicado: (2023)

Short tail stories: the hirudin-like factors HLF6 and HLF7 of the Asian medicinal leech, Hirudinaria manillensis
por: Müller, Christian, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia
por: Grover, Punita, et al.
Publicado: (2022)

Successful therapy of chimeric antigen receptor T cells for isolated extramedullary acute lymphoblastic leukemia
por: Li, Xiangqun, et al.
Publicado: (2022)

Advantages and Limitations of SNP Array in the Molecular Characterization of Pediatric T-Cell Acute Lymphoblastic Leukemia
por: Lejman, Monika, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
por: Greenbaum, Uri, et al.
Publicado: (2020)

Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia
por: Zhang, Xian, et al.
Publicado: (2020)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Chimeric antigen receptor T-cells in B-acute lymphoblastic leukemia: history, current situation, and future
por: Muller, Bradley J., et al.
Publicado: (2023)

Peripheral Bone Relapse of Paediatric TCF3-HLF Positive Acute Lymphoblastic Leukaemia during Haematopoietic Stem Cell Transplantation: A Case Report
por: Horváth, Máté, et al.
Publicado: (2022)

The goat β-casein/CMV chimeric promoter drives the expression of hLF in transgenic goats produced by cell transgene microinjection
por: Zhang, Ting, et al.
Publicado: (2019)

Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia
por: An, Furun, et al.
Publicado: (2020)

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
por: Zhang, Cheng, et al.
Publicado: (2022)

The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
por: Ragoonanan, Dristhi, et al.
Publicado: (2022)

Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: Two case reports
por: Zhu, Yang-min, et al.
Publicado: (2016)

Decreased HLF Expression Predicts Poor Survival in Lung Adenocarcinoma
por: Wang, Zaiyan, et al.
Publicado: (2021)

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
por: Wei, Guoqing, et al.
Publicado: (2017)

Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction
por: Hong, Ruimin, et al.
Publicado: (2021)

Neuropsychiatric disorders in adults undergoing chimeric antigen receptor T cells therapy for aggressive lymphomas and acute lymphoblastic leukemia
por: Emole, Josephine, et al.
Publicado: (2023)

Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission
por: Hu, Guan-hua, et al.
Publicado: (2022)

Comprehensive chromosomal aberrations in a case of a patient with TCF3-HLF-positive BCP-ALL
por: Lejman, Monika, et al.
Publicado: (2020)

Modern Immunotherapy of Adult B-Lineage Acute Lymphoblastic Leukemia with Monoclonal Antibodies and Chimeric Antigen Receptor Modified T Cells
por: Maino, Elena, et al.
Publicado: (2015)

Pediatric acute lymphoblastic leukemia
por: Inaba, Hiroto, et al.
Publicado: (2020)

BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes
por: Wu, Shuiyan, et al.
Publicado: (2021)

Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Bernt, Kathrin M., et al.
Publicado: (2014)

Pediatric Medical Care System in China Has Significantly Reduced Abandonment of Acute Lymphoblastic Leukemia Treatment
por: Zhou, Qi, et al.
Publicado: (2015)

Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view
por: Thielen, Frederick W., et al.
Publicado: (2020)

Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Hlf marks the developmental pathway for hematopoietic stem cells but not for erythro-myeloid progenitors
por: Yokomizo, Tomomasa, et al.
Publicado: (2019)

CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months
por: Yao, Zhenzhen, et al.
Publicado: (2023)

Isolated Intraocular Relapse of Pediatric B-cell Precursor Acute Lymphoblastic Leukaemia Following Chimeric Antigen Receptor T-lymphocyte Therapy
por: Veys, Delphine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3l9bikpubssg1k7uld2odvnuo6